POTELIGEO Drug Profile

Summary for Tradename: POTELIGEO

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for POTELIGEO

Recent Clinical Trials for POTELIGEO

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Yale University	Phase 2
Kyowa Kirin, Inc.	Phase 2
H. Lee Moffitt Cancer Center and Research Institute	EARLY_PHASE1

See all POTELIGEO clinical trials

Pharmacology for POTELIGEO

Mechanism of Action	Chemokine Receptor Type 4 Interactions
Established Pharmacologic Class	Chemokine Receptor Type 4 Interaction Monoclonal Antibody
Chemical Structure	Antibodies, Monoclonal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for POTELIGEO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for POTELIGEO Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for POTELIGEO Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Poteligeo

Last updated: February 21, 2026

What is Poteligeo?

Poteligeo ( mogamulizumab-kpkc) is a monoclonal antibody developed by Kyowa Kirin that targets CCR4, a chemokine receptor expressed on certain immune cells. It is approved for cutaneous T-cell lymphoma (CTCL) and adult T-cell leukemia/lymphoma (ATLL) in various markets.

Market Overview

The global biologics market is expanding at a compound annual growth rate (CAGR) of 10%-12%. The oncology segment, specifically, accounts for approximately 30% of the total biologics revenue, driven by rising incidence rates of hematologic malignancies and expanding indications for targeted therapies like Poteligeo.

Regulatory Status and Approvals

• United States (FDA): Approved in August 2018 for CTCL in adult patients who have received at least one prior systemic therapy. Not approved for ATLL in the U.S.
• European Union (EMA): Approved in February 2019 for CTCL.
• Japan (PMDA): Approved in 2018 for CTCL and ATLL.

Market Penetration and Reimbursement

• US: Reimbursement is available through Medicare and commercial insurers. Adoption in second-line CTCL remains moderate due to competition.
• Europe: Reimbursement varies by country; access is limited outside large healthcare institutions.
• Japan: Reimbursement is supported by national health insurance, facilitating broader access, particularly for ATLL.

Competitive Landscape

Key Competitors

Drug Name	Indications	Approval Year	Phase of Competition
Brentuximab vedotin	Various lymphomas	2012, 2018	Alternative in certain T-cell lymphomas
Mogamulizumab	CTCL, ATLL	2018, 2019	First-line and later-line options
Alemtuzumab	T-cell leukemias	2001	Off-label in some cases

Differentiation Factors

• Mechanism: Poteligeo's CCR4 targeting offers specific tumor cell modulation.
• Safety Profile: Lower rates of severe adverse events compared to some competitors.
• Dosing Convenience: Requires monthly infusions, which could impact patient compliance.

Commercial Performance and Revenue Trajectory

Historical Revenue

Year	Revenue (USD millions)	Launch Year
2018	$50	2018
2019	$120	2019
2020	$180	2020
2021	$250	2021

Future Financial Outlook

• Projected CAGR (2022-2027): 15%-20%, driven by expanding indications and geographic penetration.
• Key Factors:
  • Launch in additional territories such as Canada and Australia.
  • Potential approval for first-line CTCL treatment.
  • Expansion into other CCR4-positive malignancies.

Challenges and Risks

• Market Saturation: Increasing competition from other targeted antibodies and combination therapies.
• Pricing and Reimbursement: Variability could limit revenue growth in certain regions.
• Indication Expansion: Regulatory hurdles or lack of demonstration of clinical benefits could constrain growth.

Strategic Growth Opportunities

• Combination Regimens: Potential to pair Poteligeo with other agents like brentuximab vedotin or immune checkpoint inhibitors.
• Biomarker Development: Enhancing patient selection to improve response rates.
• Global Expansion: Entry into underserved markets with high prevalence rates of T-cell lymphomas.

Key Takeaways

Poteligeo is a niche biologic with strong positioning in second-line CTCL and ATLL. Market growth hinges on expanding indications, geographic penetration, and competitive differentiation. Revenue is expected to grow at a high double-digit CAGR over the next five years, although risks from market competition and reimbursement factors remain.

FAQs

1. How does Poteligeo compare to other treatments in efficacy?
   It shows comparable or superior efficacy in specific patient populations, especially in relapsed/refractory CTCL, with a favorable safety profile.

2. What are the main barriers to market expansion?
   Regulatory approval in new regions, competition from established therapies, and reimbursement challenges.

3. Can Poteligeo be combined with other therapies?
   Yes, ongoing studies are evaluating combination regimens, which could expand its use.

4. What is the timeline for potential new indications?
   Clinical trial data for first-line treatment expectations are within 2-3 years, potentially leading to regulatory review.

5. What are the key markets for Poteligeo outside of the U.S.?
   Europe, Japan, and emerging markets in Asia-Pacific represent significant opportunities.

---

References

[1] MarketsandMarkets. (2022). Biologics Market by Therapy Area, Drug Type, and Region.
[2] Kyowa Kirin. (2023). Poteligeo (mogamulizumab-kpkc) prescribing information.
[3] European Medicines Agency. (2022). Product information: Poteligeo.
[4] U.S. Food and Drug Administration. (2018). Approval letter: Poteligeo.